Neo-Adjuvant
NSABP B-40
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients withPalpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for (pCR) with Each of the Regimens

NSABP B-41
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpapable & Operable Her2 Positive Breast Cancer Comparing the combination of Trastuzumab Plus Lapatinib vs Trastuzumab vs Lapatinib administered with weekly Paclitaxel following AC

Adjuvant
ECOG E5103
A Double –Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.

NSABP B-42
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer

NSABP B44 – BETH
(Adjuvant Therapy for Patients with Her-2 positive, node positive or High Risk Node Negative Breast) TCH®H q 3 wks x 6 ®H X 1yr +/- Bevacizumab x 1 yr

NSABP FB-5
A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxes Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant for HER2-Positive Pathologic Stage III Breast Cancer

IBCSG 24-02
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer Tamoxifen versus Ovarian function suppression + tamoxifen versus Ovarian function suppression + exemestane

ECOG PACCT-1
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Taylor X Trial Assigning Individualized Options for Treatment The TAILORx Trial Oncotype Dx Assay for ER and/or PR-Positive, Negative nodes, Tumor size 1.1-5.0 cm (or 5mm-1.0cm plus unfavorable histological features), Her2/neu negative. Oncotype Dx Assay test must be done

Advanced Breast Cancer

CINJOG 040702 (triple negative untreated Metastatic breast)
Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer

CINJOG 040706 ( Phase I & II 1st line post menopausal Hormone receptive positive, locally advanced or Metastatic Breast)
Letrozole(Femara) & Sorafenib (Nexavar taken orally daily. (Phase I part of the trial will be done in NB to determine the dosing, after that we can accrue.)

CINJ 040608 (NJ 1106)
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients with HER2-Overexpressing Advanced Metastatic Breast Cancer